News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Pfizer Inc. and Ranbaxy Laboratories Deal Would Delay Generic Lipitor
June 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (Reuters) - Pfizer Inc. said on Wednesday that Ranbaxy Laboratories Ltd can begin selling a U.S. generic form of its Lipitor cholesterol fighter by late 2011 under a settlement deal, some five months later than Wall Street expectations.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Pfizer
MORE ON THIS TOPIC
Artificial intelligence
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
October 15, 2026
·
1 min read
·
Annalee Armstrong
Deals
Stoffels strikes up new biotech in return to Galapagos cell therapy mission
October 15, 2026
·
4 min read
·
Annalee Armstrong
Licensing
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
October 14, 2026
·
1 min read
·
Annalee Armstrong
Obesity
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
October 14, 2026
·
3 min read
·
Tristan Manalac
